Table 3.

Differentially expressed miRNAs in pPCL compared with multiple myeloma samples

miRNAa, bSAM scorecmiRNAa, bSAM scorec
has-miR-217.34hsa-miR-513b−5.75
has-miR-301a5.13hsa-miR-513a-5p−5.35
has-miR-374a4.98hsa-miR-494−4.61
has-miR-330-3p4.79hsa-miR-513c−4.47
has-miR-4544.71hsa-miR-638−4.06
has-miR-142-3p4.68hsa-miR-193b*−4
has-miR-155*4.38hsa-miR-1224-5p−3.61
has-miR-301b4.29hsa-miR-193a-5p−3.57
has-miR-140-5p4.09hsa-miR-222−3.5
has-miR-18a4.03hsa-miR-145−3.49
has-miR-99a3.95hsa-miR-23a*−3.46
has-miR-590-5p3.95hsa-miR-221−3.4
has-miR-362-3p3.94hsa-miR-139-3p−3.37
hsa-miR-1553.91hsa-miR-423-5p−3.13
hsa-miR-7-1*3.9hsa-miR-1226*−3.08
hsa-miR-21*3.47hsa-miR-126−3.05
hsa-miR-628-5p3.32hsa-miR-1225-5p−3
hsa-miR-20a*3.22hsa-let-7a−2.95
hsa-miR-18b3.17hsa-miR-572−2.91
hsa-miR-19a3.15hsa-miR-671-5p−2.91
hsa-miR-29b-1*3.1hsa-miR-663−2.89
hsa-miR-6603.07hsa-miR-765−2.86
hsa-miR-4242.93hsa-miR-874−2.84
hsa-miR-142-5p2.81hsa-miR-188-5p−2.8
hsa-miR-1002.76hsa-miR-370−2.8
hsa-miR-1032.59hsa-miR-636−2.77
hsa-miR-532-5p2.56hsa-miR-135a*−2.71
hsa-miR-181d2.56hsa-miR-345−2.68
hsa-miR-72.54hsa-miR-34c-3p−2.55
hsa-miR-26b2.53hsa-miR-1234−2.52
hsa-miR-125b2.53hsa-miR-193b−2.47
hsa-miR-3402.52hsa-miR-221*−2.46
hsa-miR-374b2.52hsa-miR-1229−2.46
hsa-miR-362-5p2.49hsa-miR-877*−2.38
hsa-miR-20b2.48hsa-miR-625*−2.34
hsa-miR-982.46hsa-miR-324-3p−2.3
hsa-miR-551b2.45hsa-miR-96−2.21
hsa-miR-181a*2.33hsa-miR-148a−2.19
hsa-miR-505*2.3hsa-miR-483-5p−2.17
hsa-miR-542-3p2.27hsa-miR-1228−2.16
hsa-miR-2102.18hsa-miR-223−2.14
hsa-miR-500*2.15
  • amiRNAs in bold are those whose trend of expression from multiple myeloma to pPCL was significantly maintained (Jonckheere–Terpstra test, P < 0.005) when considering the healthy controls.

  • bmiRNAs in italic are those that are differentially expressed between pPCL from proprietary cohort and multiple myeloma cases from GEO series GSE17306.

  • cUp- and downregulated miRNAs are ordered according to SAM scores.